0 CHECKOUT

Bacterial Vaginosis - Pipeline Review, H1 2015

  • ID: 3099673
  • January 2015
  • 49 pages
  • Global Markets Direct
1 of 4

Bacterial Vaginosis - Pipeline Review, H1 2015

Summary

This, ‘Bacterial Vaginosis - Pipeline Review, H1 2015’, provides an overview of the Bacterial Vaginosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following READ MORE >

Note: Product cover images may vary from those shown
2 of 4

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Bacterial Vaginosis Overview
Therapeutics Development
Pipeline Products for Bacterial Vaginosis - Overview
Pipeline Products for Bacterial Vaginosis - Comparative Analysis
Bacterial Vaginosis - Therapeutics under Development by Companies
Bacterial Vaginosis - Therapeutics under Investigation by Universities/Institutes
Bacterial Vaginosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bacterial Vaginosis - Products under Development by Companies
Bacterial Vaginosis - Products under Investigation by Universities/Institutes
Bacterial Vaginosis - Companies Involved in Therapeutics Development
AmVac AG
Osel Inc.
Starpharma Holdings Limited
Valeant Pharmaceuticals International, Inc.
Bacterial Vaginosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMV-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LACTIN-V - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Product-55394 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
secnidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bacterial Vaginosis - Recent Pipeline Updates
Bacterial Vaginosis - Dormant Projects
Bacterial Vaginosis - Discontinued Products
Bacterial Vaginosis - Product Development Milestones
Featured News & Press Releases
Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis
Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
Apr 03, 2013: Starpharma Announces Positive Results From Phase II Study Of VivaGel For Prevention Of Recurrent Bacterial Vaginosis
Nov 28, 2012: Starpharma Announces Results From Two Phase III Studies Of VivaGel For Treatment Of Bacterial Vaginosis
Oct 18, 2012: Starpharma Completes Recruitment In Two Phase III Trials Of VivaGel For Treatment For Bacterial Vaginosis
Jun 25, 2012: Starpharma Completes Patient Recruitment For Phase II And First Pivotal Phase III Trials Of VivaGel
Jun 04, 2012: Starpharma Completes 60% Patient Recruitment For Phase III Trials Of VivaGel
Jan 11, 2012: Starpharma Receives FDA Special Protocol Assessment For Phase III Trials Of VivaGel For Treatment Of Bacterial Vaginosis
Nov 21, 2011: Starpharma Secures European Agreement On BV Phase III Treatment
Oct 10, 2011: Starpharma Secures FDA Agreement On Phase III VivaGel Bacterial Vaginosis Treatment Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bacterial Vaginosis, H1 2015
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Bacterial Vaginosis - Pipeline by AmVac AG, H1 2015
Bacterial Vaginosis - Pipeline by Osel Inc., H1 2015
Bacterial Vaginosis - Pipeline by Starpharma Holdings Limited, H1 2015
Bacterial Vaginosis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Bacterial Vaginosis Therapeutics - Recent Pipeline Updates, H1 2015
Bacterial Vaginosis - Dormant Projects, H1 2015
Bacterial Vaginosis - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Bacterial Vaginosis, H1 2015
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

AmVac AG
Osel Inc.
Starpharma Holdings Limited
Valeant Pharmaceuticals International, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.